Clinical Trial Update: Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating postoperative radiotherapy combined with panitumumab for high-risk salivary gland cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Athanassios Argiris | Conditions: Salivary Gland Malignancy | Phase 2 | Status: WITHDRAWN